|
|
|||
(TNF-
). The other, efalizumab, targets CD11a, or
L, one chain of
L
2 integrin, also known as leukocyte-functionassociated antigen 1 (LFA-1); LFA-1 is important in the process by which T cells cross blood-vessel walls, enter tissue, and are subsequently activated by antigen. Increasingly, molecules that were once the exclusive domain of immunologic scientists have entered mainstream medicine.
Etanercept consists of the
Source Information
From the Department of Dermatology, Brigham and Women's Hospital, Boston.
Related Letters:
Etanercept for Crohn's Disease
Travers S. B., Kupper T. S.
Extract |
Full Text |
PDF
N Engl J Med 2004;
350:840, Feb 19, 2004.
Correspondence
This article has been cited by other articles:
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved. |